Real-World Efficacy and Safety of Universal 8-Week Glecaprevir/Pibrentasvir for Treatment-Naïve Patients from a Nationwide HCV Registry in Taiwan.

Chun-Chi YangChung-Feng HuangTe-Sheng ChangChing-Chu LoChao-Hung HungChien-Wei HuangLee-Won ChongPin-Nan ChengMing-Lun YehCheng-Yuan PengChien-Yu ChengJee-Fu HuangMing-Jong BairChih-Lang LinChi-Chieh YangSzu-Jen WangTsai-Yuan HsiehTzong-Hsi LeePei-Lun LeeWen-Chih WuChih-Lin LinWei-Wen SuSheng-Shun YangChia-Chi WangJui-Ting HuLein-Ray MoChun-Ting ChenYi-Hsiang HuangChun-Chao ChangChia-Sheng HuangGuei-Ying ChenChien-Neng KaoChi-Ming TaiChun-Jen LiuMei-Hsuan LeeHsing-Tao KuoPei-Chien TsaiChia-Yen DaiJia-Horng KaoHan-Chieh LinWang-Long ChuangKuo-Chih TsengChi-Yi ChenMing-Lung Yu

Published in: Infectious diseases and therapy (2024)

Eight-week GLE/PIB therapy was effective and well tolerated in all TN patients, regardless of cirrhosis status.

Keyphrases

end stage renal disease
ejection fraction
prognostic factors
peritoneal dialysis
randomized controlled trial
clinical trial
stem cells
mesenchymal stem cells
antiretroviral therapy
smoking cessation